DelveInsight’s Atypical Hemolytic Uremic Syndrome market report thoroughly explains the Atypical Hemolytic Uremic Syndrome historical and forecasted epidemiology and the Atypical Hemolytic Uremic Syndrome market trends in the 7MM.
Some of the Important Findings from the Atypical Hemolytic Uremic Syndrome Market Report
-
According to the aHUS foundation, Atypical Hemolytic Uremic Syndrome has the “ultra-rare” designation, which is reserved for diseases that affect fewer than 20 people per million.
-
As per DelveInsight estimates, the total aHUS prevalent cases were 7.0 thousand in the 7MM in 2020, which is further expected to increase by 2030.
-
According to the estimates, the total aHUS diagnosed cases were over 2 thousand in the US in 2020.
-
The key players in the aHUS market include Roche, Novartis, and others.
-
Key aHUS therapies in the pipeline include Iptacopan (LNP023), Crovalimab (RG6107, SKY59), and others.
-
Iptacopan, also known as LNP023, is a first-in-class, orally-administered, small-molecule, potent, and highly selective factor B (FB) inhibitor, an essential serine protease of the complement cascade’s alternative pathway.
Request for a sample to know more @ Atypical Hemolytic Uremic Syndrome Market Outlook
Atypical Hemolytic Uremic Syndrome: Overview
Atypical Hemolytic Uremic Syndrome (aHUS) is a disease that causes abnormal blood clots to form in the kidneys’ tiny blood vessels. If these clots restrict or block blood flow, they can cause serious medical problems such as hemolytic anaemia, thrombocytopenia, and kidney failure.
Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation
The Atypical Hemolytic Uremic Syndrome report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
-
Atypical Hemolytic Uremic Syndrome Total Prevalent Cases
-
Atypical Hemolytic Uremic Syndrome Total Diagnosed Cases
-
Atypical Hemolytic Uremic Syndrome Total Age Group-Specific Cases
-
Atypical Hemolytic Uremic Syndrome Total Treated Cases
Atypical Hemolytic Uremic Syndrome Treatment Landscape
The current aHUS treatment option includes Conventional Therapy (Plasma Therapy, Dialysis, diuretics, Anti-hypertensive). Some FDA-approved drugs, such as Soliris (eculizumab) and Ultomiris (ravulizumab), by Alexion Pharmaceuticals, are also for aHUS treatment.
Atypical Hemolytic Uremic Syndrome Market Outlook
The current Atypical Hemolytic Uremic Syndrome therapeutic landscape is dominated by approved therapies such as Soliris and Ultomiris. The introduction of new developmental candidates such as Iptacopan (LNP023), Crovalimab (RG6107, SKY59), and others currently in the pipeline are expected to impact the Atypical Hemolytic Uremic Syndrome market during the forecast period (2021-2030).
Get a detailed analysis of the market @ Atypical Hemolytic Uremic Syndrome Therapeutic Market
Atypical Hemolytic Uremic Syndrome Pipeline Therapies and Key Companies
Iptacopan (LNP023): Novartis
Crovalimab (RG6107, SKY59): Roche
Table of Contents
|
1. |
Key Insights |
|
2. |
Report Introduction |
|
3. |
Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance |
|
4. |
Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS) |
|
5. |
aHUS Epidemiology and Market Methodology |
|
6. |
aHUS Disease Background and Overview |
|
7. |
Diagnosis and Differential Diagnosis of Atypical Hemolytic Uremic Syndrome |
|
8. |
aHUS Diagnostic Guidelines |
|
9. |
Current Treatment Practices of Atypical Hemolytic Uremic Syndrome |
|
10. |
aHUS Treatment Guidelines |
|
11. |
Conclusion |
|
12. |
aHUS Epidemiology and Patient Population |
|
13. |
aHUS Patient Journey |
|
14. |
Key Endpoints in Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials |
|
15. |
aHUS Marketed Therapies |
|
16. |
aHUS Emerging Therapies |
|
17. |
Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis |
|
18. |
aHUS Market Access and Reimbursement |
|
19. |
KOL Views |
|
20. |
aHUS Market Drivers |
|
21. |
aHUS Market Barriers |
|
22. |
SWOT Analysis |
|
23. |
aHUS Unmet Needs |
|
24. |
Appendix |
|
25. |
DelveInsight Capabilities |
|
26. |
Disclaimer |
|
27. |
About DelveInsight |
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Warm Autoimmune Hemolytic Anemia Market
DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) – Market Insights, Epidemiology and Market Forecast-2030′ report deliver an in-depth understanding of the disease, historical &forecasted epidemiology, as well as the market trends of WAIHAs in the 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/